Endo International plc has entered into an agreement with the subsidiaries of Strides Pharma to sell its manufacturing site in Chestnut Ridge, New York. Endo noted that “the exit of this site was included in a series of business transformation initiatives that the company announced in late 2020, including further optimizing of the company's generic retail business cost structure.”
The $24m deal – in cash, as well as certain other non-cash considerations – also involves Strides acquiring an undisclosed...
